Posted on 1/25/18
Johnson & Johnson: Dividend King And Dividend Growth, Buy The Dip, 20% Upside Potential
Johnson & Johnson Has increased its dividend for 55 years in a row (a dividend king) and presently has a yield of 2.4% which is above . . .
Posted on 1/25/18
Johnson & Johnson Backs Away From Pfizer's Consumer Health Unit
Reuters reports that Johnson & Johnson (JNJ +1%) has withdrawn from the list of potential suitors for Pfizer's (PFE +0.3%) consumer health business, leaving GlaxoSmithKline (GSK) . . .
Posted on 1/25/18
Johnson & Johnson: Expect Underwhelming Results To Continue
Despite the gains of the last year, Johnson & Johnson (JNJ) hasn't actually outperformed the market. In fact, the stock has now vastly underperformed the market . . .
Posted on 1/25/18
Johnson & Johnson: Buying On The Dip
Johnson & Johnson (NYSE: JNJ) has been a core position in my portfolio and is likely a core position in many other portfolios. Even for passive . . .
Posted on 1/25/18
Johnson & Johnson Down Small on Huge Loss -- What Gives?
On this episode of the Market Foolery podcast, Chris Hill chats with Jim Mueller from Stock Advisor and Motley Fool Options and Abi Malin of Hidden . . .
Posted on 1/25/18
Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc.(Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing of an underwritten . . .
Posted on 1/25/18
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today . . .
Posted on 1/24/18
AngelMD’s Catalyst Fund Invests in Six Startups During Alpha Conference
Investment platform takes a direct role in the success of six companies ahead of the JP Morgan Healthcare Conference.AngelMD announced that its Catalyst LP I Fund . . .
Posted on 1/24/18
AngelMD Releases 2017 Private Investment In Healthcare Technology Report
A new report sheds light on private-sector investment in healthcare technology AngelMD collated public data and proprietary data from its network to provide deep insights into . . .
Posted on 1/24/18
Nomad Health Launches First Freelance Marketplace for Physicians and Nurses in New York to Solve Clinician Shortages
NEW YORK--(BUSINESS WIRE)--Nomad Health, the online marketplace for healthcare jobs, today announced that it is expanding its platform to all physicians and nurses in its home . . .
Posted on 1/24/18
Cigna Named a "Best Place to Work for LGBTQ Equality" for Sixth Year in a Row
BLOOMFIELD, Conn.--(BUSINESS WIRE)--Cigna (NYSE: CI), a global health service company, received a perfect 100 score on the Human Rights Campaign's 2018 Corporate Equality Index (CEI) and . . .
Posted on 1/24/18
Rocket Pharmaceuticals Prices Public Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading U.S.-based multi-platform gene therapy company, today announced the pricing of an underwritten public offering of 5,500,000 shares . . .
Posted on 1/24/18
Johnson & Johnson: Buy The 1st 4% Drop Since March 2009
Johnson & Johnson (JNJ) reported earnings yesterday morning and beat estimates on both the top and bottom line, but shares traded down over 4%. The decline . . .
Posted on 1/24/18
Celgene (CELG) Announces Acquisition Of Juno Therapeutics - Slideshow
The following slide deck was published by Celgene Corporation in conjunction with this event. 125READ FULL ARTICLE HERE
Posted on 1/24/18
How To Trade Johnson & Johnson After Slump On U.S. Tax Charges
Johnson & Johnson (JNJ) opened Tuesday at $146.96 after trading as high as $151.00 pre-market on an initial positive reaction to earnings. The open was below . . .
Posted on 1/24/18
Celgene's Investments Are Soaring
Celgene Corp.'s (NASDAQ:CELG) acquiring its collaboration partner, Juno Therapeutics, for $9 billion, and that's fueling investor interest in Celgene's other collaboration partners. bluebird bio (NASDAQ:BLUE), Jounce . . .
Posted on 1/24/18
Tax Losses Mask Johnson & Johnson's Fundamental Strength
Tax reform has been a hot-button issue with corporate America during the current earnings season, and as one of the largest multinational conglomerates in the world, . . .
Posted on 1/24/18
UroGen Pharma Announces Closing of Upsized Public Offering
RA’ANANA, Israel and NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in . . .
Posted on 1/24/18
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q4 2017 Results - Earnings Call Transcript
Hello. I am Joe Walk, Vice President of Investor relations for Johnson & Johnson. Welcome to our company’s review of business results for the fourth quarter . . .
Posted on 1/23/18
Rocket Pharmaceuticals Proposes Public Offering of Common Stock
NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading U.S.-based multi-platform gene therapy company, today announced that it has commenced an underwritten public offering. Rocket also intends . . .
Posted on 1/23/18
Johnson & Johnson: What's About To Happen?
Article thesisJohnson & Johnson (JNJ) reports fourth quarter results on Tuesday and has a good chance of beating estimates again. Due to consistent growth, great diversification . . .
Posted on 1/23/18
Merck Has Strong Conviction In KalVista's Phase 2 Clinical Trial Of KVD001 In DME
BackgroundKalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company focused on the development of small molecule protease inhibitors. The company is still in its infancy and market . . .
Posted on 1/23/18
Whom Will Pfizer Buy in 2018?
It's going to happen.I have no doubt that Pfizer (NYSE:PFE) will make a significant acquisition this year. After a couple of notable deals in 2016, the . . .
Posted on 1/23/18
Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors?
It's now official.Reports generated excitement last week that Celgene (NASDAQ:CELG) planned to buy out Juno Therapeutics (NASDAQ:JUNO). Neither company commented on the rumors then. But Monday . . .
Posted on 1/23/18
Why 2017 Was a Year to Forget for Regeneron Pharmaceuticals, Inc.
2017 was a good year for biotech investors. The iShares Nasdaq Biotechnology ETF(NASDAQ:IBB) rose 21%, which was a smidge ahead of the S&P 500's performance. However, . . .

